Eli Lilly announces positive interim proof-of-concept data from BLAZE-1 phase II trial of antibody therapy LY-COV555 against COVID-19

The 2800 mg dose of this neutralizing IgG1 monoclonal antibody directed against spike “S” protein on SARS-CoV-2 hit the primary endpoint (change from baseline in viral load at day 11) but the other doses and placebo did not.


Biospace Inc.